A major new review from the Cochrane Collaboration has reignited debate around anti-amyloid therapies for Alzheimer’s disease, prompting strong responses from researchers, charities and patient advocacy organisations across the UK.
The review, which analysed data from 17 clinical trials involving more than 20,000 participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease, concluded that “the absolute effects of anti-amyloid drugs on cognitive decline and dementia severity were absent or trivial”. The review also highlighted increased risks of brain swelling and bleeding associated with these treatments.
These conclusions have generated significant concern across the dementia research community, particularly because many experts believe the review does not fully reflect the progress made by newer anti-amyloid medicines.
Concerns Over “Pooled Data”
One of the strongest criticisms centres on the way the review grouped together results from 17 separate trials, of which 15 were either unsuccessful or discontinued.
Leading dementia research organisations argued that combining older failed treatments with newer medicines such as Lecanemab and Donanemab creates a misleading overall picture.
ReMind UK Research & Medical Director, Dr Tomas Welsh responds;
ReMindUK welcomes continued discussion and scrutiny of emerging treatments for Alzheimer’s disease, alongside careful evaluation of the evidence supporting them. It is important, however, that reviews of anti-amyloid therapies clearly distinguish between earlier treatments that were unsuccessful in late-stage trials and newer medicines that have demonstrated measurable clinical benefit.
Dr Welsh continues, ” Experts have noted that combining these different groups of drugs may limit how accurately the current evidence is represented.
In particular, Lecanemab and Donanemab have been shown to slow disease progression in people with early Alzheimer’s disease. While these treatments are not a cure and will not be the whole answer to tackling Alzheimer’s, they represent meaningful scientific progress and an important step forward for patients and families. More broadly, Alzheimer’s research is advancing rapidly, with a growing number of clinical trials exploring a wide range of biological pathways and therapeutic approaches.
While important discussions remain around implementation, access and long-term impact, there is broad agreement on one central issue: people affected by Alzheimer’s disease urgently need effective new treatment options.”
While these treatments are not a cure and will not be the whole answer to tackling Alzheimer’s, they represent meaningful scientific progress and an important step forward for patients and families.
Protecting Hope and Future Research
There is also concern that headlines suggesting anti-amyloid drugs are ineffective could discourage participation in dementia clinical trials at a time when research participation is urgently needed.
Researchers stress that failed trials are part of scientific progress. Understanding what does not work helps improve the next generation of treatments. New late-stage trials are already underway, building on lessons learned from earlier studies.
There is broad agreement across the sector that anti-amyloid drugs are not a silver bullet. They come with risks, access challenges and important questions around long-term impact. But most experts also agree they should not be viewed as the end of the road.
For people living with Alzheimer’s disease and their families, the urgent need for better treatment options remains unchanged. The challenge now is ensuring that scientific debate reflects the full complexity of the evidence, and does not undermine the hope that improved treatments are on the horizon.
Take part in dementia research
More news & views
Supporting communication in dementia: building connection, confidence, and care
Effective communication is at the heart of quality dementia care. The Supporting Communication in Dementia workshop at Dorothy House offers a valuable opportunity for people living with mild to moderate dementia and their communication partners to strengthen understanding, connection, and emotional wellbeing.
Depression and dementia risk: What the latest research shows
Depression and dementia are more closely linked than once thought. The Lancet 2024 report identifies depression in midlife as a potentially modifiable risk factor for dementia. While the exact link is unclear, changes in lifestyle, social engagement, and stress-related brain effects may play a role.
How dementia research is making a real difference for carers: John’s story
When John Desmond’s wife, Linda, was diagnosed with semantic dementia in 2021 at the age of 67, it marked the beginning of a new chapter for them both. Semantic dementia, a form of frontotemporal dementia, affects a person’s ability to use and understand words.